TABLE 1

Baseline demographics and clinical characteristicsa

CharacteristicResult for patients receiving:P value
VAN (n = 131)DAP (n = 131)
Median (IQR) age (yr)57.0 (46.0–70.0)56.0 (43.0–61.0)0.095
Median (IQR) Pitt bacteremia score3 (2–3)3 (2–3)0.933
Median (IQR) baseline CRCL (ml/min)61.6 (37.9–84.0)60.4 (40.3–82.5)0.885
No. (%) of patients with:
    AKI on admission45 (34.4)44 (33.6)0.896
    History of DM43 (32.8)50 (38.2)0.366
    HIV/AIDS9 (6.9)10 (7.6)0.812
    CHD22 (16.8)20 (15.3)0.736
    i.v. drug use34 (26.0)35 (26.7)0.888
    CKD (not HD)16 (12.2)24 (18.3)0.169
    Liver disease21 (16.0)30 (22.9)0.160
    Antibiotic use in past 30 days33 (25.2)27 (20.6)0.262
    Vancomycin use in past 30 days12 (9.2)7 (5.3)0.341
    Hospitalization in past year66 (50.4)65 (49.6)0.902
    Surgery in past 30 days5 (3.8)14 (10.7)0.032
    MRSA infection in past year7 (5.3)16 (12.2)0.049
No. (%) of patients with the following primary site of infection:0.572
    Bone/joint27 (20.6)38 (29.0)
    Skin/soft tissue33 (25.2)30 (22.9)
    Deep abscess14 (10.7)14 (10.7)
    Infective endocarditis23 (17.6)25 (19.1)
    i.v. catheter15 (11.5)10 (7.6)
    Other19 (14.5)14 (10.7)
  • a AKI, acute kidney injury; DAP, daptomycin; DM, diabetes mellitus; CHD, congestive heart disease; CKD, chronic kidney disease; CRCL, creatinine clearance; HD, hemodialysis; IQR, interquartile range; VAN, vancomycin.